vs

Side-by-side financial comparison of Lifeway Foods, Inc. (LWAY) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.

SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $55.4M, roughly 1.2× Lifeway Foods, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 4.6%, a 34.8% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $-17.4M).

Lifeway Foods is an Illinois-based health food company founded in 1986. They are a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome.

SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.

LWAY vs SLNO — Head-to-Head

Bigger by revenue
SLNO
SLNO
1.2× larger
SLNO
$66.0M
$55.4M
LWAY
Higher net margin
SLNO
SLNO
34.8% more per $
SLNO
39.4%
4.6%
LWAY
More free cash flow
SLNO
SLNO
$60.9M more FCF
SLNO
$43.5M
$-17.4M
LWAY

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
LWAY
LWAY
SLNO
SLNO
Revenue
$55.4M
$66.0M
Net Profit
$2.5M
$26.0M
Gross Margin
27.8%
98.3%
Operating Margin
6.8%
33.5%
Net Margin
4.6%
39.4%
Revenue YoY
18.0%
Net Profit YoY
1688.1%
134.0%
EPS (diluted)
$0.15
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LWAY
LWAY
SLNO
SLNO
Q4 25
$55.4M
Q3 25
$57.1M
$66.0M
Q2 25
$53.9M
$32.7M
Q1 25
$46.1M
Q4 24
$46.9M
Q3 24
$46.1M
Q2 24
$49.2M
Q1 24
$44.6M
Net Profit
LWAY
LWAY
SLNO
SLNO
Q4 25
$2.5M
Q3 25
$3.5M
$26.0M
Q2 25
$4.2M
$-4.7M
Q1 25
$3.5M
Q4 24
$-160.0K
Q3 24
$3.0M
Q2 24
$3.8M
Q1 24
$2.4M
Gross Margin
LWAY
LWAY
SLNO
SLNO
Q4 25
27.8%
Q3 25
28.7%
98.3%
Q2 25
28.6%
97.9%
Q1 25
23.9%
Q4 24
25.3%
Q3 24
25.7%
Q2 24
27.0%
Q1 24
25.8%
Operating Margin
LWAY
LWAY
SLNO
SLNO
Q4 25
6.8%
Q3 25
8.8%
33.5%
Q2 25
10.8%
-20.0%
Q1 25
3.4%
Q4 24
1.5%
Q3 24
9.1%
Q2 24
11.0%
Q1 24
8.0%
Net Margin
LWAY
LWAY
SLNO
SLNO
Q4 25
4.6%
Q3 25
6.2%
39.4%
Q2 25
7.9%
-14.4%
Q1 25
7.7%
Q4 24
-0.3%
Q3 24
6.5%
Q2 24
7.7%
Q1 24
5.4%
EPS (diluted)
LWAY
LWAY
SLNO
SLNO
Q4 25
$0.15
Q3 25
$0.23
$0.47
Q2 25
$0.28
$-0.09
Q1 25
$0.23
Q4 24
$0.00
Q3 24
$0.19
Q2 24
$0.25
Q1 24
$0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LWAY
LWAY
SLNO
SLNO
Cash + ST InvestmentsLiquidity on hand
$5.6M
$498.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$85.8M
$494.8M
Total Assets
$105.6M
$599.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LWAY
LWAY
SLNO
SLNO
Q4 25
$5.6M
Q3 25
$23.0M
$498.9M
Q2 25
$21.2M
$286.8M
Q1 25
$19.4M
Q4 24
$16.7M
Q3 24
$20.6M
Q2 24
$14.6M
Q1 24
$12.0M
Total Debt
LWAY
LWAY
SLNO
SLNO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$2.5M
Stockholders' Equity
LWAY
LWAY
SLNO
SLNO
Q4 25
$85.8M
Q3 25
$82.8M
$494.8M
Q2 25
$78.7M
$240.1M
Q1 25
$74.2M
Q4 24
$71.9M
Q3 24
$71.5M
Q2 24
$68.0M
Q1 24
$63.5M
Total Assets
LWAY
LWAY
SLNO
SLNO
Q4 25
$105.6M
Q3 25
$109.5M
$599.9M
Q2 25
$98.3M
$332.3M
Q1 25
$93.7M
Q4 24
$90.5M
Q3 24
$91.3M
Q2 24
$84.9M
Q1 24
$82.8M
Debt / Equity
LWAY
LWAY
SLNO
SLNO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LWAY
LWAY
SLNO
SLNO
Operating Cash FlowLast quarter
$267.0K
$43.5M
Free Cash FlowOCF − Capex
$-17.4M
$43.5M
FCF MarginFCF / Revenue
-31.5%
65.8%
Capex IntensityCapex / Revenue
31.9%
0.0%
Cash ConversionOCF / Net Profit
0.11×
1.67×
TTM Free Cash FlowTrailing 4 quarters
$-16.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LWAY
LWAY
SLNO
SLNO
Q4 25
$267.0K
Q3 25
$6.9M
$43.5M
Q2 25
$3.9M
$-12.6M
Q1 25
$-150.0K
Q4 24
$-2.6M
Q3 24
$7.5M
Q2 24
$6.5M
Q1 24
$1.5M
Free Cash Flow
LWAY
LWAY
SLNO
SLNO
Q4 25
$-17.4M
Q3 25
$1.8M
$43.5M
Q2 25
$1.6M
$-12.6M
Q1 25
$-2.4M
Q4 24
$-3.8M
Q3 24
$5.9M
Q2 24
$5.1M
Q1 24
$-923.0K
FCF Margin
LWAY
LWAY
SLNO
SLNO
Q4 25
-31.5%
Q3 25
3.1%
65.8%
Q2 25
3.0%
-38.6%
Q1 25
-5.1%
Q4 24
-8.2%
Q3 24
12.8%
Q2 24
10.4%
Q1 24
-2.1%
Capex Intensity
LWAY
LWAY
SLNO
SLNO
Q4 25
31.9%
Q3 25
9.0%
0.0%
Q2 25
4.3%
0.0%
Q1 25
4.8%
Q4 24
2.7%
Q3 24
3.3%
Q2 24
2.9%
Q1 24
5.5%
Cash Conversion
LWAY
LWAY
SLNO
SLNO
Q4 25
0.11×
Q3 25
1.96×
1.67×
Q2 25
0.92×
Q1 25
-0.04×
Q4 24
Q3 24
2.50×
Q2 24
1.73×
Q1 24
0.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LWAY
LWAY

Drinkable Kefirotherthan Pro Bugs$47.8M86%
Cheese$4.7M8%
Cream And Other$1.7M3%
Other$1.2M2%

SLNO
SLNO

Segment breakdown not available.

Related Comparisons